Inventiva: Financial Visibility Until Early 2027, NATiV3 Scheduled for Q4 2026
On Tuesday, Inventiva released its Q1 2026 financial results, highlighting the critical trajectory of its cash reserves. The French biotech specializing in the development of an oral therapy for MASH has 75 million euros in cash and equivalents, with an additional 121.5 million euros in short-term deposits, totaling 196.5 million euros. Without further capital injections, the company estimates it can fund its operations only until mid-Q1 2027, while major clinical results are not expected until Q4 2026.
Cash Reserves Decline Over Three Months
As of March 31, 2026, Inventiva reported cash and equivalents of 75 million euros, coupled with 121.5 million euros in short-term deposits, for a total liquidity reserve of 196.5 million euros. This amount represents a decrease of 34.4 million euros compared to the end of 2025 (99.3 million euros in cash plus 131.6 million euros in short-term deposits, totaling 230.9 million euros). This cash flow decrease directly stems from operational expenses related to the development program of lanifibranor, the phase 3 drug candidate currently being evaluated by the biotech. No revenue was recorded in the first quarter of 2026, a situation identical to that of 2025.
Narrowing Financing Window
Given its current cost structure and forecasted expenditures, Inventiva anticipates that its cash reserves and deposits will fund its operations until mid-Q1 2027. This timeline provides just over nine months of visibility. However, the company has a fallback option: the exercise of Tranche 3 warrants issued as part of the structured financing announced in October 2024. A full exercise of these instruments would generate an additional 116 million euros, extending the runway until mid-Q3 2027. However, there are no guarantees regarding their partial or full exercise.
NATiV3 Data at the Heart of the Strategy
Key results from the pivotal NATiV3 clinical trial are expected in the fourth quarter of 2026. These results represent a significant clinical milestone for the development of lanifibranor, but the release reminds that no guarantees can be provided regarding the timeline, trial outcomes, or future regulatory steps. The company is participating in upcoming international conferences (EASL in Barcelona from May 27 to 30, Jefferies Global Healthcare Conference in June) to maintain visibility among potential investors and partners.
